Nuveen’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-751,508
| Closed | -$17.8M | – | 3316 |
|
|
2023
Q4 | $17.8M | Buy |
751,508
+52,116
| +7% | +$928K | 0.01% | 1231 |
|
|
2023
Q3 | $10.4M | Buy |
699,392
+400,517
| +134% | +$5.31M | ﹤0.01% | 1457 |
|
|
2023
Q2 | $3.27M | Buy |
+298,875
| New | +$2.78M | ﹤0.01% | 2119 |
|
|
2022
Q2 | – | Sell |
-287,914
| Closed | -$924K | – | 3547 |
|
|
2022
Q1 | $924K | Buy |
287,914
+5,245
| +2% | +$16.5K | ﹤0.01% | 2843 |
|
|
2021
Q4 | $897K | Sell |
282,669
-23,178
| -8% | -$88K | ﹤0.01% | 2894 |
|
|
2021
Q3 | $1.17M | Sell |
305,847
-5,040
| -2% | -$19.9K | ﹤0.01% | 2935 |
|
|
2021
Q2 | $1.35M | Sell |
310,887
-49,691
| -14% | -$220K | ﹤0.01% | 2882 |
|
|
2021
Q1 | $1.64M | Buy |
360,578
+33,867
| +10% | +$182K | ﹤0.01% | 2706 |
|
|
2020
Q4 | $1.88M | Buy |
326,711
+74,991
| +30% | +$568K | ﹤0.01% | 2547 |
|
|
2020
Q3 | $1.82M | Sell |
251,720
-9,998
| -4% | -$53.5K | ﹤0.01% | 2429 |
|
|
2020
Q2 | $913K | Sell |
261,718
-131,867
| -34% | -$381K | ﹤0.01% | 2653 |
|
|
2020
Q1 | $583K | Sell |
393,585
-389,603
| -50% | -$654K | ﹤0.01% | 2720 |
|
|
2019
Q4 | $1.53M | Buy |
783,188
+450,435
| +135% | +$1.69M | ﹤0.01% | 2527 |
|
|
2019
Q3 | $1.7M | Sell |
332,753
-11,293
| -3% | -$68.4K | ﹤0.01% | 2477 |
|
|
2019
Q2 | $2.46M | Buy |
+344,046
| New | +$3.9M | ﹤0.01% | 2338 |
|
Other funds holding CBAY
Nuveen's CBAY Position: Q1 2024 in Review
Nuveen sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 751,508 shares — an estimated $17.8M sold.
Nuveen first reported a position in CBAY in Q2 2019 and held it in 15 quarters. The position peaked at $17.8M in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Nuveen reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Nuveen sold 751,508 Cymabay Therapeutics shares in Q1 2024, an estimated $17.8M.
- Nuveen first reported a position in Cymabay Therapeutics in Q2 2019 and held it in 15 quarters.
- Nuveen's Cymabay Therapeutics position peaked at $17.8M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Nuveen's 13F filing for Q1 2024, filed 13 May 2024.